|
May 29
|
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
|
|
May 22
|
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
|
|
Apr 23
|
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
|
|
May 15
|
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
|
May 9
|
Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...
|
|
Apr 29
|
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
|
|
Apr 24
|
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
|
|
Apr 24
|
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
|
|
Apr 16
|
Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity
|
|
Apr 16
|
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
|
|
Apr 16
|
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
|
|
Apr 16
|
Cullinan changes name, pivots to autoimmune disease
|
|
Mar 16
|
Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 15
|
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
|
|
Mar 14
|
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 1
|
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
|
|
Feb 27
|
Cullinan Oncology to Participate in Upcoming Investor Conferences
|
|
Dec 18
|
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 14
|
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
|
|
Nov 8
|
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
|